The World Health Organization has predicted over 20 million new cancer cases in 2015 worldwide. This seemingly unbelievable number is not only astonishing; it is also a dire warning from the WHO. With the future onslaught of patients needing cancer care and treatments, the WHO has been urging researchers to continue to develop new products[…]
Will Bortezomib Meet the WHO Need for Future Cancer Treatments?
Bulk Active Ingredient, Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, Patent Expiration 2017 Tags: Bortezomibmantle cell lymphomamultiple myelomaWHO Jan 31, 2013
Iloprost favors the quitters in the battle against lung cancer
Antithrombotic, Cardiovascular Agent, Drug Research & Development API, Prostaglandin Tags: antihypertensiveprostaglandinWHO Oct 05, 2011
In a world where about a third of the adult male in the global population smokes, it’s tough not to take notice of its negative impact on the society as a whole. According to the WHO, if the smoking trends do not ease up, one in every 6 adults will die of smoking-related illness (e.g.[…]
Antiangiogenic Agents – Providing an Alternative Approach
Bulk Active Ingredient, Chemotherapeutic / Anti-Neoplastic Tags: 114977-28-5BevacizumabDocetaxelWHO May 02, 2011
A recent study conducted by the Queens University Belfasts School of Pharmacy revealed the ability of the recombinant protein FKBPL to inhibit tumor growth by disrupting the blood supply to these tumors. This method of cancer treatment called neovascularization is certainly not new with several agents exhibiting the same mode of action already available in[…]
